Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.1K
Cross-bridge Cycle01:26

Cross-bridge Cycle

108.4K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
108.4K
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

24
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
24
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

19
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
19
Neural Regulation01:37

Neural Regulation

34.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
34.5K
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

13
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
13

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Learning a distance for the clustering of patients with amyotrophic lateral sclerosis.

BioData mining·2026
Same author

Reversible & Microbubble Concentration-Dependent Permeabilization of an <i>In Vitro</i> Human Endothelial Barrier to Small Molecules Using Ultrasound: Implications for Neurodegenerative Diseases Therapy.

Molecular pharmaceutics·2026
Same author

Anchoring ALS Prognosis: Neurofilament Light Chain Outperforms Inflammatory, Metabolic, and CNS Barrier Biomarkers in the METABALS Cohort.

Molecular neurobiology·2026
Same author

From Mutation to Manifestation: Penetrance in Amyotrophic Lateral Sclerosis.

Genes·2026
Same author

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Clinical, Electrophysiological, and Neuropathological Features of Peripheral Neuropathies in People With T-Cell Lymphoproliferative Disorder.

Neurology·2026
Same journal

Feasibility and sensitivity of a multimodal digital endpoint panel for amyotrophic lateral sclerosis: a prospective cohort study.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

Reduced penetrance in genetic ALS/FTD spectrum disorders: implications for genetic counseling, predictive testing and treatment.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

An open-label Phase 2a study of fasudil in amyotrophic lateral sclerosis: safety and exploratory endpoints.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

Noninvasive assessment of cardiovascular autonomic reflexes in amyotrophic lateral sclerosis: a systematic review.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

The connection between unproven stem cell-based interventions and complementary and alternative medicine in crowdfunding for Amyotrophic Lateral Sclerosis.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

Thinning of the oral motor cortex is linked to impaired speech in amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
See all related articles

Related Experiment Video

Updated: Apr 23, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

33.3K

Is there a paraneoplastic ALS?

Philippe Corcia1, Paul H Gordon, Jean-Philippe Camdessanche

  • 1ALS Centre, CHU Tours.

Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|October 7, 2014
PubMed
Summary
This summary is machine-generated.

Paraneoplastic syndrome (PNS) is a rare cause of Amyotrophic Lateral Sclerosis (ALS). Evaluating specific clinical features and onconeuronal antibodies can suggest malignancy in ALS patients.

Keywords:
Motor neuron diseasesparaneoplasticreview

More Related Videos

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

27.9K
A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS
12:43

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS

Published on: February 21, 2011

37.6K

Related Experiment Videos

Last Updated: Apr 23, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

33.3K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

27.9K
A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS
12:43

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS

Published on: February 21, 2011

37.6K

Area of Science:

  • Neurology
  • Oncology

Background:

  • Investigating the link between paraneoplastic syndrome (PNS) and Amyotrophic Lateral Sclerosis (ALS).
  • Assessing the strength of evidence for PNS as a cause of ALS and identifying associated clinical features.

Observation:

  • Literature review focused on concurrent ALS and neoplasia, primarily case reports and small series.
  • Three tiers of evidence support a paraneoplastic etiology for ALS: onconeuronal antibodies, co-occurrence with known PNS-causing neoplasms, and co-occurrence with non-classical neoplasms.

Findings:

  • Most ALS-neoplasm cases do not represent a classically established PNS.
  • Elevated onconeuronal antibodies or specific neoplasms suggest PNS is a rare cause of ALS.

Implications:

  • Clinical features like rapid progression, non-motor signs, and specific demographics (elderly females, young onset) warrant neoplasm evaluation in ALS.
  • Highlights the importance of considering PNS in the differential diagnosis of ALS, albeit rare.